CTLA-4 (CD152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesia region

Archivum Immunologiae et Therapiae Experimentalis

Volumn 52, Issue 5, 2004, Pages 369-374

  Frydecka, Irena ^a,b   Daroszewski, Jacek ^b   Suwalska, Katarzyna ^a   Zołedziewska, Magdalena ^b   Tutak, Anna ^a   Słowik, Mirosław ^b   Potoczek, Stanisław ^b   Dobosz, Tadeusz ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

A(49)G; CTLA 4; Graves' disease; Lower Silesia

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; ENDOCRINE OPHTHALMOPATHY; EXON; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; GRAVES DISEASE; HEREDITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLAND; POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; EXONS; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 10344228267     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Abe T., Takino H., Yamasaki H., Ozaki M., Sera Y., Kondo H., Sakamaki H., Kawaski E., Awata T., Yamaguchi Y. and Eguchi K. (1999): CTLA-4 gene polymorphism correlates with the mode of onset and presence of ICA512 Ab in Japanese type 1 diabetes. Diabetes Res. Clin. Pract., 46, 169-175.
2. Allahabadia A., Heward J. M., Nithiyanathan R., Gibson S. M., Reuser T. T., Dodson P. M., Franklyn J. A. and Gough S. C. (2001): MHC class II region, CTLA-4 gene, and ophthalmopathy in patients with Graves' disease. Lancet, 358, 984-985.
3. Anjos S., Nguyen A., Ounissi-Benkalha H., Tessiert M. C. and Polychronakos C. (2002): A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem., 277, 46478-46486.
4. Awata T., Kurihara S., Iitaka M., Takei S., Inoue I., Ishii C., Negishi K., Izumida T., Yoshida Y., Hagura R., Kuzuya N., Kanazawa Y. and Katayama S. (1998): Association of CTLA-4 gene A-G polymorphism (IIDM12 locus) with acute-onset and insulin-depleted IIDS as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in Japanese population. Diabetes, 47, 128-129.
5. Badenhoop K., Donner H., Braun J., Siegmund T., Rau H. and Usadel K. H. (1996): Genetic markers in diagnosis and prediction of relapse in Graves' disease. Exp. Clin. Endocrinol. Diabetes, 104 (suppl. 4), 98-100.
6. Barbesino G., Tomer Y., Concepcion E. S., Davies T. F. and Greenberg D. A. (1998): Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender related genes and the X-chromosome. J. Clin. Endocrinol. Metab., 83, 3290-3295.
7. Bednarczuk T., Hiromatsu Y., Fukutani T., Jazdzewski K., Miskiewicz P., Osikowska M. and Nauman J. (2003): Association of cytotoxic T-lymphocyte- associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur. J. Endocrinol., 148, 13-18.
8. Boćko D., Bilińska M., Dobosz T., Żół ȩdziewska M., Suwalska K., Tutak A., Gruszka E. and Frydecka I. (2003): Lack of association between an exon 1 CTLA-4 gene polymorphism A(49)G and multiple sclerosis in a Polish population of the Lower Silesia region. Arch. Immunol. Ther. Exp., 51, 201-205.
9. Buzzetti R., Nistico L., Signore A. and Cascino I. (1999): CTLA-4 and HLA gene susceptibility to thyroid-associated orbitopathy. Lancet, 354, 1824.
10. Chambers C. A. and Allison J. P. (1997): Co-stimulation in T cell responses. Curr. Opin. Immunol., 9, 396-404.
11. Chen Q. Y., Nadell D., Zhang X. Y., Kukreja A., Huang Y. J., Wise J., Svec F., Richards R., Friday K. E., Vargas A., Gomez R., Chalew S., Lan M. S., Tomer Y. and Maclaren N. K. (2000): The human leukocyte antigen HLA DR*020/Dqa1*0501 haplotype is associated with Graves' disease in African Americans. J. Clin. Endocrinol. Metab., 85, 1545-1549.
12. Chistiakov D. A. and Turakulov R. I. (2003): CTLA-4 and its role in autoimmune thyroid disease. J. Mol. Endocrinol., 31, 21-36.
13. Colucci F., Bergman M. L., Penha-Goncalves C., Cilio C. M. and Holmberg D. (1997): Apoptosis resistance of no-obese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc. Natl. Acad. Sci. USA, 94, 8670-8674.
14. Davies T. F. (2000): Graves' disease: pathogenesis. In Braverman L. E. and Utiger R. D. (eds.): Werner and Ingbar's the thyroid: a fundamental and clinical text. Wiliams & Wikens, Philadelphia, 518-530.
15. Degroot L. J. and Qintans J. (1989): The causes of autoimmune thyroid disease. Endocrinol. Rev., 10, 537-562.
16. Deichmann K., Heinzmann A., Bruggenolte E., Forster J. and Kuehr J. (1996): An Mse 1 RFLP in the human CTLA-4 promotor. Biochem. Biophys. Res. Commun., 225, 817-818.
17. Djilali-Saiah I., Larger L., Harfouch-Hammoud E., Timsit J., Clere J., Bertin E., Assan R., Boitard C., Bach J. F. and Caillat-Zueman S. (1998): No major role for the CTLA-4 gene in the association of autoimmune thyroid disease with IDDM. Diabetes, 47, 125-127.
18. Donner H., Rau H., Walfish P. G., Braun J., Thorsten S., Finke R., Herwig J., Usadel K. H. and Badenhoop K. (1997): CTLA-4 alanine-17 confers genetic susceptibility to Graves' disease and type 1 diabetes mellitus. J. Clin. Endocrinol. Metab., 82, 143-146.
19. Gribben J. G., Freeman G. J., Boussiotis V. A., Rennert P., Jellis C. A., Jellis C. A., Greenfield E., Barber M., Restivo V. A. Jr., Ke X., Gray S.C. and Nadler L. M. (1995): CTLA-4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA, 92, 811-815.
20. Harper K., Balzano C., Rouvier E., Mattei M. G., Luciani M. F. and Golstein P. (1991): CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J. Immunol., 147, 1037-1044.
21. Heward J. M., Allahabadia A., Armitage M., Hattersley A., Dodson P., Macleod K., Carr-Smith J., Daykin J., Daly A., Sheppard M. C., Holder R. L., Barnett A. H., Franklyn J. A. and Gough C. L. (2000): The development of Graves' disease and CTLA-4 gene on chromosome 2q33. Endocrinol. Metab., 84, 2398-2401.
22. Heward J. M., Allahabadia A., Carr-Smith J., Daykin J., Cockram C. S., Gordon C., Barnett A. H., Franklyn J. A. and Gough S. C. (1998): No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family - based studies. Clin. Endocrinol., 49, 331-334.
23. Heward J. M., Allahabadia A., Daykin J., Carr-Smith J., Daly A., Armitag E. M., Dodson P. M., Sheppard M. C., Barnett A. H., Franklyn J. A. and Gough S. C. (1998): Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family - based study. J. Clin. Endocrinol. Metab., 83, 3394-3397.
24. Heufelder A. E. (2000): Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev. Endocr. Metab. Disord., 1, 87-95.
25. Hurvitz A. A., Sullivan T. J., Krummel M. F., Sobel R. A. and Allison J. P. (1997) Specific blockade of CTLA-4/B7 interaction results exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol., 73, 57-62.
26. Karandikar N. J., Vanderlunrt C. L., Walunas T. L., Miller S. D. and Bluestone J. A. (1996): CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med., 184, 783-788.
27. Kosmaczewska A., Ciszak L., Boćko D. and Frydecka I. (2001): Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch. Immunol. Ther. Exp., 49, 39-46.
28. Kotsa K., Watson P. F. and Weetman A. P. (1997): The CTLA-4 gene polymorphism is associated with both Graves' disease and autoimmune hyperthyroidism. Clin. Endocrinol., 46, 551-554.
29. Kouki T., Gardine C. A., Yanagawa T. and Degroot L. J. (2002): Relation of three polymorphism of the CTLA-4 gene in patients with Graves' disease. J. Endocrinol. Invest., 25, 208-213.
30. Kouki T., Sawai Y., Gardine C. A., Fisfalen M. E., Alegre M. L. and DeGroot L. J. (2000): CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J. Immunol., 165, 6606-6611.
31. Kristiansen O. P., Larsen Z. M. and Pociot F. (2000): CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun., 1, 170-184.
32. Maurer M., Loserth S., Kolb-Maurer A., Ponath A., Wiese S., Kruse N. and Rieckmann P. (2002): A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene (exon 1 +49) alters T-cell activation. Immunogenetics, 54, 1-8.
33. Nistico L. Buzzetti R., Pritchard L. E., Van Der Auwera B., Giovannini C., Bosi E., Larrad M. T., Rios M. S., Chow C. C., Cockram C. S., Jacobs K., Mijovic C., Bain S. C., Barnett A. H., Vandewalle C. L., Schuit F., Gorus F. K., Tosi R., Pozzilli P. and Todd J. A. (1996): The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with type 1 diabetes. Hum. Mol. Genet., 5, 1075-1080.
34. Perros P., Crombie A. L., Matthews J. N. S. and Kendall-Taylor P. (1993): Age and gender influence the severity of thyroid-associated ophthalmopathy. Clin. Endocrinol., 38, 367-372.
35. Polymeropoulos M. H., Xiao H., Rath D. S. and Merril C. R. (1991): Dinucleotide repeat polymorphism at the human CTLA-4 gene. Nucleic Acids Res., 19, 4018.
36. Stassi G. and Dc Maria R. (2002): Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat. Rev. Immunol., 2, 195-204.
37. Tivol E. A., Borriello F., Schweitzer A. N., Lynch W. P., Bluestone J. A. and Sharpe A. H. (1995): Loss of CTLA-4 leads to massive lymphoproliferation and multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3, 541-547.
38. Tomer Y., Barbesino G., Greenberg D. A., Conception E. S. and Davies T. F. (1998): A new Graves' disease susceptibility locus maps to chromosome 20q11.2. Am. J. Hum. Genet., 63, 1749-1756.
39. Tomer Y., Barbesino G., Greenberg D. A., Conception E. S. and Davies T. F. (1998): Linkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localises GD-1 close to MNG-1. J. Clin. Endocrinol. Metab., 83, 4321-4327.
40. Tomer Y. and Davies T. F. (2003): Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr. Rev., 24, 694-717.
41. Ueda H., Howson J. M. M., Esposito L., Heward J., Snook H., Chamberlain G. Rainbow D. B., Hunter K. M., Smith A. N., Di Genova G., Herr M. H., Dahlman I., Payne F., Smyth D., Lowe C., Twells R. C., Howlett S., Healy B., Nutland S., Rance H. E., Everett V., Smink L. J., Lam A. C., Cordell H. J., Walker N. M., Bordin C., Hulme J., Motzo C., Cucca F., Hess J. F., Metzker M. L., Rogers J., Gregory S., Allahabadia A., Nithiyananthan R., Tuomilehto-Wolf E., Tuomilehto J., Bingley P., Gillespie K. M., Undlien D. E., Ronningen K. S., Guja C., Ionescu-Tirgoviste C., Savage D. A., Maxwell A. P., Carson D. J., Patterson C. C., Franklyn J. A., Clayton D. G., Peterson L. B., Wicker L. S., Todd J. A. and Gough S. C. (2003): Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature, 423, 506-511.
42. Waterhouse P., Penninger J. M., Timms E., Wakeham A., Shahinian A., Lee K. P., Thompson C. B., Griesser H. and Mak T. W. (1995): Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science, 270, 985-988.
43. Wiersing W. M. and Bartalena L. (2002): Epidemiology and prevention of Graves' ophthalmopathy. Tyroid, 12, 855-860.
44. Werner S. C. (1977): Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J. Clin. Endocrinol., 44, 203-204.
45. Vaidya B., Imrie H., Perros P., Dickinson J., Mccarthy M. I., Kendall-Taylor P. and Pearce S. H. S. (1999): Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid-associated orbitopathy. Lancet, 354, 743-744.
46. Villanueva R., Inzerillo A. M., Tomer Y., Barbesino G., Meltzer M., Concepcion E. S., Greenberg D. A., Maclaren N., Sun Z. S., Zhang D. M., Tucci S. and Davies T. F. (2000): Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid, 10, 791-798.
47. Yanagawa T., Hidaka Y., Guimaraes V. and Soliman M. (1995): CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab., 80, 41-45.